Imprimis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch IMMY and buy or sell other stocks, ETFs, and their options commission-free!

About IMMY

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. 

CEO
Mark L. Baum
CEOMark L. Baum
Employees
373
Employees373
Headquarters
Nashville, Tennessee
HeadquartersNashville, Tennessee
Founded
2006
Founded2006
Employees
373
Employees373

IMMY Key Statistics

Market cap
234.17M
Market cap234.17M
Price-Earnings ratio
-219.76
Price-Earnings ratio-219.76
Dividend yield
Dividend yield
Average volume
19.75K
Average volume19.75K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$54.85
52 Week high$54.85
52 Week low
$21.12
52 Week low$21.12

Stock Snapshot

With a market cap of 234.17M, Imprimis Pharmaceuticals(IMMY) trades at $6.29. The stock has a price-to-earnings ratio of -219.76.

Imprimis Pharmaceuticals(IMMY) stock opened on 2026-04-12 at —. The price climbed to — and dipped to —.

The Imprimis Pharmaceuticals(IMMY)'s current trading volume is 0, compared to an average daily volume of 19.75K.

In the last year, Imprimis Pharmaceuticals(IMMY) shares hit a 52-week high of $54.85 and a 52-week low of $21.12.

In the last year, Imprimis Pharmaceuticals(IMMY) shares hit a 52-week high of $54.85 and a 52-week low of $21.12.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.